Innate Pharma SA Class A

Innate Pharma SA Class A's next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2026, Innate Pharma SA Class A has 93.90M shares outstanding.

As of June 30, 2026, Innate Pharma SA Class A maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Innate Pharma SA Class A holds 10.90M in cash and equivalents against 20.21M in total debt, resulting in a net debt position of 13.61M. Total book value stands at -40.51M, with working capital of -13.26M providing operational flexibility.